International Business Machines Corporation

IBM remains in a longer-term recovery regime, with the 50-day average above the 200-day average and the shares still below the 52-week high. The stock is trading close to its 200-day line, so the setup is constructive but not yet fully broken out.

Street sentiment is mixed but leaning constructive: the published consensus sits at Hold, while the average target of 311.33 is above the current share price. Recent actions skew positive, including fresh Overweight/Buy calls and multiple target resets in the $290 to $350 range.

IBM heads into the next report after a solid beat pattern, with 5 of the last 7 quarters topping estimates. The next quarter is modeled at $3.02 EPS, up from the prior beat cycle, and shareholders should watch whether software and consulting keep supporting the higher full-year earnings path.

No discretionary insider buying or selling stands out. Recent activity is dominated by director awards and a small officer gift, which reads as routine compensation flow rather than a directional signal.

Profitability is strong, with a 58.4% gross margin, 13.8% operating margin, and 15.6% net margin. Growth is steady rather than explosive: revenue rose 9.5% year over year and earnings grew 14.2%, while free cash flow reached $14.81 billion in fiscal 2025.

IBM’s appeal is steadier cash generation and lower volatility than many software peers, backed by a 0.665 beta and a 5.68% free-cash-flow yield. The valuation is not cheap at 24.41x earnings, but it is supported by recurring services and hybrid cloud exposure.